The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. Bavarian Nordic has reached an agreement to sell a priority review voucher (PRV) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback